EGFR and non-small cell lung carcinoma: Recent trials have investigated the synergistic effects of combining osimertinib with Mesenchymal-Epithelial Transition (MET) inhibitors to overcome MET amplification-mediated resistance, a common mechanism in EGFR-TKI-resistant NSCLC.